Qian Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qian Zhang has a total of 177 co-authors. Here are the top co-authors by number of shared publications:
Xinru Xiao
Department of Respiratory and Critical Care Medicine, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, 213164, China
10 shared publicationsYan Qian
Department of Respiratory and Critical Care Medicine, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, 213164, China
10 shared publicationsZiqi Ding
Department of Respiratory and Critical Care Medicine The Second People's Hospital of Changzhou The Third Affiliated Hospital of Nanjing Medical University Changzhou China
10 shared publicationsYujia Shi
Department of Respiratory and Critical Care Medicine The Second People's Hospital of Changzhou The Third Affiliated Hospital of Nanjing Medical University Changzhou China
9 shared publicationsZhengdao Mao
Department of Respiratory and Critical Care Medicine, The Affiliated Changzhou Second People’s Hospital of Nanjing Medical University, Changzhou, China
8 shared publicationsYi Chen
The Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, Changzhou, China
7 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Springer Nature in BMC Pulmonary Medicine
Effectiveness of Tele-rehabilitation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis
- 6 November 2026
- Published by Springer Nature in BMC Pulmonary Medicine
Open AccessEffectiveness of Tele-rehabilitation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis
- Open Access
- 25 October 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1873 (2) , 168509
TOMM5-glycolysis-Mlxipl axis: A novel mechanistic insight into idiopathic pulmonary fibrosis
- 25 October 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1873 (2) , 168509
Open AccessTOMM5-glycolysis-Mlxipl axis: A novel mechanistic insight into idiopathic pulmonary fibrosis
- Open Access
- 27 September 2026
- Published by Wiley in Advanced Science
- p. e19533
Copper‐Driven Epithelial Barrier Disruption: A Novel Mechanism of COPD Acute Exacerbations Mediated by the TNF‐α/ATP7A Axis
Elevated copper levels are associated with chronic obstructive pulmonary disease (COPD) and susceptibility to acute exacerbations of COPD (AECOPD), but the underlying mechanisms remain unclear. This study aimed to investigate the association between copper levels and AECOPD and elucidate the underlying mechanisms. A cross‐sectional analysis of NHANES 2011–2012, a hospital‐based case‐control study enrolling 30 AECOPD patients and 30 healthy controls, and a one‐year prospective follow‐up of COPD patients demonstrated that higher serum copper levels were associated with more frequent exacerbations and earlier recurrence. Integrated studies using copper‐manipulated COPD mice, zebrafish, lung organoids, and BEAS‐2B cells, together with bulk and single‐cell RNA sequencing, colorimetric copper quantification, ELISA‐based tumor necrosis factor‐α (TNF‐α) measurement, oxidative stress and mitochondrial functional analyses, and FITC‐dextran permeability assays, showed that excess copper induced mitochondrial oxidative stress, tight‐junction loss, and epithelial barrier dysfunction. Mechanistic analyses revealed that TNF‐α suppressed ATPase copper‐transporting alpha (ATP7A) transcription through competition between NF‐κB and CREB1 for the shared coactivator CBP, thereby promoting intracellular copper accumulation. ATP7A restoration alleviated epithelial injury, whereas ATP7A silencing abolished the improvement conferred by anti‐TNF‐α therapy in COPD mice. These findings identify the copper–TNF‐α/ATP7A axis as a mechanism underlying AECOPD and a potential therapeutic target.
- 27 September 2026
- Published by Wiley in Advanced Science
- p. e19533
Open AccessCopper‐Driven Epithelial Barrier Disruption: A Novel Mechanism of COPD Acute Exacerbations Mediated by the TNF‐α/ATP7A Axis
Elevated copper levels are associated with chronic obstructive pulmonary disease (COPD) and susceptibility to acute exacerbations of COPD (AECOPD), but the underlying mechanisms remain unclear. This study aimed to investigate the association between copper levels and AECOPD and elucidate the underlying mechanisms. A cross‐sectional analysis of NHANES 2011–2012, a hospital‐based case‐control study enrolling 30 AECOPD patients and 30 healthy controls, and a one‐year prospective follow‐up of COPD patients demonstrated that higher serum copper levels were associated with more frequent exacerbations and earlier recurrence. Integrated studies using copper‐manipulated COPD mice, zebrafish, lung organoids, and BEAS‐2B cells, together with bulk and single‐cell RNA sequencing, colorimetric copper quantification, ELISA‐based tumor necrosis factor‐α (TNF‐α) measurement, oxidative stress and mitochondrial functional analyses, and FITC‐dextran permeability assays, showed that excess copper induced mitochondrial oxidative stress, tight‐junction loss, and epithelial barrier dysfunction. Mechanistic analyses revealed that TNF‐α suppressed ATPase copper‐transporting alpha (ATP7A) transcription through competition between NF‐κB and CREB1 for the shared coactivator CBP, thereby promoting intracellular copper accumulation. ATP7A restoration alleviated epithelial injury, whereas ATP7A silencing abolished the improvement conferred by anti‐TNF‐α therapy in COPD mice. These findings identify the copper–TNF‐α/ATP7A axis as a mechanism underlying AECOPD and a potential therapeutic target.
- Open Access
- 23 April 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
Dopamine signaling governs macrophage-mediated acute lung injury through JAML/IL-10-coupled mitochondrial regulation
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) remain devastating clinical entities characterized by uncontrolled pulmonary inflamm
- 23 April 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
Open AccessDopamine signaling governs macrophage-mediated acute lung injury through JAML/IL-10-coupled mitochondrial regulation
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) remain devastating clinical entities characterized by uncontrolled pulmonary inflamm
- 20 August 2025
- Published by Elsevier in Phytomedicine
- Vol. 147, 157183
Mechanistic insights into baicalein's anti-inflammatory effects in COPD: Targeting oxidative stress and CD8⁺ T cell cytotoxicity
- 20 August 2025
- Published by Elsevier in Phytomedicine
- Vol. 147, 157183
Mechanistic insights into baicalein's anti-inflammatory effects in COPD: Targeting oxidative stress and CD8⁺ T cell cytotoxicity
- Open Access
- 10 July 2025
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 30 (1) , 1-3
Correction: A novel mechanism for A-to-I RNA-edited CYP1A1 in promoting cancer progression in NSCLC
- 10 July 2025
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 30 (1) , 1-3
Open AccessCorrection: A novel mechanism for A-to-I RNA-edited CYP1A1 in promoting cancer progression in NSCLC
- Open Access
- 1 May 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 6453-6466
Identifying KL-6-Associated Immune Cell Signatures and Key Genes in Emphysematous COPD
Background: This study aimed to evaluate the potential of Krebs von den lungen-6 (KL-6) as a biomarker for distinguishing emphysematous chronic obstructive pulmonary disease (COPD-E) from non-emphysematous COPD (COPD-NE), and to explore the underlying mechanisms associated with KL-6 expression. Methods: We enrolled 154 patients with COPD and 170 healthy controls to assess serum KL-6 levels. Receiver operating characteristic curve was used to determine the diagnostic sensitivity and specificity. Pearson’s correlation analysis was used to evaluate the correlation. Univariate and multivariate linear regression analyses were performed to explore the factors influencing KL-6 levels in COPD. Transcriptomic sequencing was performed on peripheral blood mononuclear cells from COPD patients with varying KL-6 levels to explore underlying biological mechanisms. A Mendelian randomization analysis was employed to ascertain the association between the expression quantitative trait loci of key genes and emphysema risk. Results: Serum KL-6 levels were significantly elevated in COPD patients, particularly in COPD-E. Pearson analyses revealed that the serum KL-6 concentration was positively correlated with eosinophil count. Transcriptomic analysis revealed 237 differentially expressed genes (DEGs) between patients with high and low levels of KL-6. Gene set enrichment analysis revealed that these DEGs were associated with immune responses. No significant difference in immune cell proportions were observed between high and low KL-6 groups, but KL-6 showed a negative correlation with T cell gamma delta. By intersecting the DEGs with those from the GSE248493 dataset, we identified seven key genes and further validated their association with the risk of emphysema using Mendelian randomization, with amidohydrolase domain containing 2 (AMDHD2) potentially reducing the risk of the disease. Conclusion: KL-6 is a promising biomarker for distinguishing COPD-E from COPD-NE and AMDHD2 may be involved in the regulation of increased KL-6 levels in COPD-E.
- 1 May 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 6453-6466
Open AccessIdentifying KL-6-Associated Immune Cell Signatures and Key Genes in Emphysematous COPD
Background: This study aimed to evaluate the potential of Krebs von den lungen-6 (KL-6) as a biomarker for distinguishing emphysematous chronic obstructive pulmonary disease (COPD-E) from non-emphysematous COPD (COPD-NE), and to explore the underlying mechanisms associated with KL-6 expression. Methods: We enrolled 154 patients with COPD and 170 healthy controls to assess serum KL-6 levels. Receiver operating characteristic curve was used to determine the diagnostic sensitivity and specificity. Pearson’s correlation analysis was used to evaluate the correlation. Univariate and multivariate linear regression analyses were performed to explore the factors influencing KL-6 levels in COPD. Transcriptomic sequencing was performed on peripheral blood mononuclear cells from COPD patients with varying KL-6 levels to explore underlying biological mechanisms. A Mendelian randomization analysis was employed to ascertain the association between the expression quantitative trait loci of key genes and emphysema risk. Results: Serum KL-6 levels were significantly elevated in COPD patients, particularly in COPD-E. Pearson analyses revealed that the serum KL-6 concentration was positively correlated with eosinophil count. Transcriptomic analysis revealed 237 differentially expressed genes (DEGs) between patients with high and low levels of KL-6. Gene set enrichment analysis revealed that these DEGs were associated with immune responses. No significant difference in immune cell proportions were observed between high and low KL-6 groups, but KL-6 showed a negative correlation with T cell gamma delta. By intersecting the DEGs with those from the GSE248493 dataset, we identified seven key genes and further validated their association with the risk of emphysema using Mendelian randomization, with amidohydrolase domain containing 2 (AMDHD2) potentially reducing the risk of the disease. Conclusion: KL-6 is a promising biomarker for distinguishing COPD-E from COPD-NE and AMDHD2 may be involved in the regulation of increased KL-6 levels in COPD-E.
- Open Access
- 2 April 2025
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 30 (1) , 1-21
A novel mechanism for A-to-I RNA-edited CYP1A1 in promoting cancer progression in NSCLC
Background: Lung cancer is the most frequently diagnosed malignancy and the leading cause of cancer-related mortality worldwide. Similar to other solid tumors, the development of non-small cell lung cancer (NSCLC) is believed to be a multistep process involving the accumulation of genetic and epigenetic alterations. A-to-I RNA editing is a widespread posttranscriptional epigenetic modification that confers specific nucleotide changes in selected RNA transcripts and plays a critical role in the pathogenesis of many human cancers. However, the mechanisms underlying A-to-I RNA editing that act as a potential driver in the pathogenesis of NSCLC progression remain incompletely elucidated. Methods: Sanger sequencing was performed to validate the CYP1A1_I462V RNA editing event in NSCLC patients. In vitro and in vivo experiments were used to assess the effects of an ADAR1-regulated CYP1A1 and its editing on NSCLC cell growth and metastasis. The crosstalk between CYP1A1_I462V RNA editing and PI3K-AKT signaling was analyzed using RNA sequencing and molecular methods. The functional role of CYP1A1_I462V in the response to oxidative stress was verified through proteomics analysis, co-IP assay, and immunofluorescence assay. Results: Sanger sequencing analysis identified an increased A-to-I RNA editing ratio of CYP1A1 in NSCLC specimens. This specific RNA editing, regulated by ADAR1, resulted in gain-of-function phenotypes characterized by enhanced tumor progression and more aggressive behavior. The edited form induced the expression of heme oxygenase-1 (HO-1) via PI3K/Akt-dependent activation compared with the wild-type CYP1A1, which led to an enhanced interaction with CYP1A1, thereby promoting the translocation of abundant HO-1 into the nucleus to resist oxidant stress in NSCLC cells. Conclusions: Our findings highlight that the I462V A-to-I RNA editing event of CYP1A1 drives pulmonary carcinogenesis through inhibiting oxidative stress and suggest that the CYP1A1-HO-1-PI3K/Akt axis may be a potential therapeutic target for NSCLC. Graphical
- 2 April 2025
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 30 (1) , 1-21
Open AccessA novel mechanism for A-to-I RNA-edited CYP1A1 in promoting cancer progression in NSCLC
Background: Lung cancer is the most frequently diagnosed malignancy and the leading cause of cancer-related mortality worldwide. Similar to other solid tumors, the development of non-small cell lung cancer (NSCLC) is believed to be a multistep process involving the accumulation of genetic and epigenetic alterations. A-to-I RNA editing is a widespread posttranscriptional epigenetic modification that confers specific nucleotide changes in selected RNA transcripts and plays a critical role in the pathogenesis of many human cancers. However, the mechanisms underlying A-to-I RNA editing that act as a potential driver in the pathogenesis of NSCLC progression remain incompletely elucidated. Methods: Sanger sequencing was performed to validate the CYP1A1_I462V RNA editing event in NSCLC patients. In vitro and in vivo experiments were used to assess the effects of an ADAR1-regulated CYP1A1 and its editing on NSCLC cell growth and metastasis. The crosstalk between CYP1A1_I462V RNA editing and PI3K-AKT signaling was analyzed using RNA sequencing and molecular methods. The functional role of CYP1A1_I462V in the response to oxidative stress was verified through proteomics analysis, co-IP assay, and immunofluorescence assay. Results: Sanger sequencing analysis identified an increased A-to-I RNA editing ratio of CYP1A1 in NSCLC specimens. This specific RNA editing, regulated by ADAR1, resulted in gain-of-function phenotypes characterized by enhanced tumor progression and more aggressive behavior. The edited form induced the expression of heme oxygenase-1 (HO-1) via PI3K/Akt-dependent activation compared with the wild-type CYP1A1, which led to an enhanced interaction with CYP1A1, thereby promoting the translocation of abundant HO-1 into the nucleus to resist oxidant stress in NSCLC cells. Conclusions: Our findings highlight that the I462V A-to-I RNA editing event of CYP1A1 drives pulmonary carcinogenesis through inhibiting oxidative stress and suggest that the CYP1A1-HO-1-PI3K/Akt axis may be a potential therapeutic target for NSCLC. Graphical
- Open Access
- 28 February 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 240, 108017
Association between lipid accumulation products and asthma among adults: Data from National Health and Nutrition Examination Survey (NHANES) 2003–2018
- 28 February 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 240, 108017
Open AccessAssociation between lipid accumulation products and asthma among adults: Data from National Health and Nutrition Examination Survey (NHANES) 2003–2018
- Open Access
- 15 February 2025
- Published by Springer Nature in Respiratory Research
- Vol. 26 (1) , 1-9
Long-term trends in the burden of asthma in China: a joinpoint regression and age-period-cohort analysis based on the GBD 2021
To develop effective strategies for controlling asthma, a thorough assessment of its disease burden is essential. In this study, we examined long-term trends in the asthma burden in China over the past three decades and analyzed its epidemiological features. We assessed the burden of asthma in China via the global burden of disease (GBD) 2021 database, focusing on prevalence, incidence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs). Additionally, we employed joinpoint analysis and age-period-cohort (apc) methods to interpret the epidemiological characteristics of asthma. Finally, we analyzed the attributable burden of asthma to gain a comprehensive understanding of its impact. The age-standardized incidence rate (ASIR) and mortality rate (ASMR) for both sexes in China shifted from 524.81 (95% UI: 421.31, 672.76) to 314.17 (95% UI: 283.22, 494.10) and from 5.82 (95% UI: 4.46, 8.50) to 1.47 (95% UI: 1.15, 1.79) per 100,000 population between 1990 and 2021. According to joinpoint analysis, the average annual percentage change (AAPC) in the age-standardized incidence rate was – 1.2 (95% CI: – 1.4, – 1.1), indicating a gradual but fluctuating decline (with significant turning points in 2005 and 2014). The apc fitting results suggest that the prevalence is now lower than it was in the past and that the relative prevalence risk is high among adolescents and middle-aged to elderly individuals, possibly due to different pathophysiological mechanisms. In 2021, the primary asthma-related burdens were metabolic risks, especially obesity. In conclusion, we found that the disease burden of asthma in China has significantly decreased. However, it remains a major concern among adolescents and elderly individuals. Metabolic risk factors, particularly obesity, are the main contributors to the asthma burden. It is essential to address specific risk factors and develop targeted public health strategies for different age groups.
- 15 February 2025
- Published by Springer Nature in Respiratory Research
- Vol. 26 (1) , 1-9
Open AccessLong-term trends in the burden of asthma in China: a joinpoint regression and age-period-cohort analysis based on the GBD 2021
To develop effective strategies for controlling asthma, a thorough assessment of its disease burden is essential. In this study, we examined long-term trends in the asthma burden in China over the past three decades and analyzed its epidemiological features. We assessed the burden of asthma in China via the global burden of disease (GBD) 2021 database, focusing on prevalence, incidence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs). Additionally, we employed joinpoint analysis and age-period-cohort (apc) methods to interpret the epidemiological characteristics of asthma. Finally, we analyzed the attributable burden of asthma to gain a comprehensive understanding of its impact. The age-standardized incidence rate (ASIR) and mortality rate (ASMR) for both sexes in China shifted from 524.81 (95% UI: 421.31, 672.76) to 314.17 (95% UI: 283.22, 494.10) and from 5.82 (95% UI: 4.46, 8.50) to 1.47 (95% UI: 1.15, 1.79) per 100,000 population between 1990 and 2021. According to joinpoint analysis, the average annual percentage change (AAPC) in the age-standardized incidence rate was – 1.2 (95% CI: – 1.4, – 1.1), indicating a gradual but fluctuating decline (with significant turning points in 2005 and 2014). The apc fitting results suggest that the prevalence is now lower than it was in the past and that the relative prevalence risk is high among adolescents and middle-aged to elderly individuals, possibly due to different pathophysiological mechanisms. In 2021, the primary asthma-related burdens were metabolic risks, especially obesity. In conclusion, we found that the disease burden of asthma in China has significantly decreased. However, it remains a major concern among adolescents and elderly individuals. Metabolic risk factors, particularly obesity, are the main contributors to the asthma burden. It is essential to address specific risk factors and develop targeted public health strategies for different age groups.